Barrington Research has increased its price target for Merit Medical Systems to $116 from $114, maintaining an Outperform rating. This adjustment follows the company's recent Q3 2026 earnings report and updated full-year guidance, suggesting a positive outlook from the analyst firm.
Barrington Research raised its price target on Merit Medical Systems (MMSI) from $114 to $116, while reiterating an Outperform rating. This move is a direct response to the company's Q3 2026 earnings report and subsequent updated full-year guidance, indicating that the analyst firm views the recent financial performance and future outlook positively. For traders, this represents a moderately positive signal, as an increased price target from a research firm can sometimes lead to short-term upward momentum in the stock. However, the change is relatively small ($2), suggesting a fine-tuning of expectations rather than a major re-rating. The long-term implications depend on whether the company continues to meet or exceed its updated guidance, validating the analyst's revised target.